Myelodysplastic syndromes (MDS) are a heterogeneous collection of hematopoietic stem cell disorders, which result in cytopenia and an increased risk of progression to acute myeloid leukemia (AML). BMS \/ Acceleron\u2019s Reblozyl (luspatercept) for lower-risk adult MDS, Astex Pharmaceuticals\u2019 Inqovi (decitabine and cedazuridine) for higher-risk adult MDS and refractory MDS, Servier\u2019s Tibsovo (ivosidenib) for relapsed or refractory MDS with an IDH1 mutation, and Geron\u2019s Rytelo (imetelstat) for low- to intermediate-1-risk adult MDS are effective treatment options. Other pharmacological approaches to managing the disease (e.g., lenalidomide [BMS\u2019s Revlimid, generics]) are designed to ameliorate symptoms and extend patients\u2019 survival, although there is a significant gap in the treatment of refractory disease. The MDS pipeline is robust and promising, and several projected market entrants are poised to penetrate the lower-risk, intermediate-risk, and higher-risk subpopulations.<\/p>\n
Questions answered<\/strong><\/p>\n Geography:<\/strong> United States and EU5<\/p>\n Primary research:<\/strong><\/p>\n Epidemiology:<\/strong> Diagnosed incident and diagnosed prevalent cases of MDS by country, diagnosed and drug-treated incident cases of MDS, diagnosed incident and prevalent cases of MDS by morphology, and diagnosed incident and prevalent cases by prognostic risk<\/p>\n Forecast: <\/strong>Drug-level sales and patient share of key MDS therapies in 2024 and 2034<\/p>\n Drug treatments:<\/strong> Coverage of key current and late-phase emerging therapies<\/p>\n Product description<\/strong><\/p>\n Niche & Rare Disease Landscape & Forecast offers comprehensive market intelligence with world-class epidemiology, keen insight into current and emerging therapies, and drug forecasts supported by detailed primary and secondary research, enabling you to:<\/p>\n\n
\n
\n<\/ul>\n
\n